Honarkar Shafie, 44 patient curcumin late treatment RCT: 29% shorter hospitalization [p=0.22] and 9% improved recovery https://c19p.org/honarkarshafie
copied to clipboard
Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial
et al., Phytotherapy Research, doi:10.1002/ptr.7374
RCT 48 hospitalized patients in Iran, 24 treated with nanocurcumin, showing lower hospitalization time with treatment. The number of patients shown in Table 3 (31 and 27 for each arm) is inconsistent with the number reported as randomized to each arm (24). 160 mg/day nanocurcumin for 6 days. IRCT20131125015536N13.
|
hospitalization time, 28.9% lower, relative time 0.71, p = 0.22, treatment mean 6.31 (±5.26) n=23, control mean 8.87 (±8.12) n=21.
|
|
relative pulmonary involvement score, 9.1% better, RR 0.91, treatment 23, control 21.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in meta
analysis:
unresolved data inconsistency.
Honarkar Shafie et al., 1/12/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, 10 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.